Qtron Investments LLC Has $1.10 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Qtron Investments LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 70.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,616 shares of the medical research company's stock after acquiring an additional 2,313 shares during the quarter. Qtron Investments LLC's holdings in IQVIA were worth $1,104,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the fourth quarter worth $33,000. Lee Danner & Bass Inc. bought a new position in IQVIA during the fourth quarter worth about $44,000. Zions Bancorporation N.A. increased its stake in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares during the last quarter. Versant Capital Management Inc raised its position in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after acquiring an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. bought a new position in IQVIA during the 4th quarter worth approximately $60,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of IQV stock traded down $4.78 on Friday, reaching $143.66. The stock had a trading volume of 3,302,597 shares, compared to its average volume of 1,403,069. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $25.33 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 1.99 and a beta of 1.46. The firm's 50-day moving average is $177.57 and its two-hundred day moving average is $197.47.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on IQV. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. UBS Group lowered their price target on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a report on Friday, February 7th. Stifel Nicolaus cut their price objective on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Finally, Robert W. Baird lowered their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, January 21st. Six equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA has an average rating of "Moderate Buy" and a consensus price target of $241.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.